Close Menu

NEW YORK (GenomeWeb) – Trovagene announced after the close of the market on Wednesday a 14 percent year-over-year drop in fourth quarter revenues. The firm also announced a restructuring program to expand into precision cancer drug development.

The liquid biopsy molecular diagnostics developer said its revenues were $68,000 for the three  months ended Dec. 31, 2016, compared to $79,000 in Q4 2015, and significantly short of the analysts' average estimate of $180,000.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.

Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.